OS

OneStream, Inc. Class A Common Stock
Inactive Not actively trading
$24.00
+0.00 (+0.00%)
Mkt Cap 2.40B
Volume 2,661,330
52W Range 16.51-29.66
Sector Technology
Beta 1.99
EPS (TTM) -0.28
P/E Ratio -66.55
Revenue (TTM) 601.93M
Rev Growth (5Y) +29.2%
EPS Growth (5Y) N/A

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022
Revenue 601.93M 489.41M 374.92M 279.32M
Net Income (50.30M) (216.20M) (28.93M) (65.47M)
EPS -0.28 -1.25 -0.85 -0.28
Free Cash Flow 95.63M 58.53M 18.68M (37.92M)
FCF / Share 0.53 0.34 0.12 -0.16
Operating CF 96.67M 61.15M 21.27M (32.94M)
Total Assets 1.03B 823.22M 361.56M 320.01M
Total Debt 14.80M 18.59M 20.03M 18.91M
Cash & Equiv 693.58M 544.17M 117.09M 14.69M
Book Value 504.71M 386.17M 106.53M 127.14M
Return on Equity -0.10 -0.56 -0.27 -0.51
OS News
OneStream, Inc. $OS Shares Bought by JPMorgan Chase & Co.
Apr 08, 2026 12:45 AM · defenseworld.net
Capricorn Fund Managers Ltd Buys New Position in OneStream, Inc. $OS
Apr 06, 2026 12:43 AM · defenseworld.net
OneStream Announces Completion of Acquisition by Hg for $6.4 Billion
Apr 01, 2026 06:37 AM · prnewswire.com
OneStream Named a 4x Leader and Placed Furthest in Vision in the 2026 Gartner Magic Quadrant for Financial Close and Consolidation Solutions
Mar 11, 2026 07:30 AM · prnewswire.com
OneStream Announces Splash 2026 and the OneStream World Tour to Help Finance Lead in a Time of Rapid Change
Mar 10, 2026 05:00 AM · prnewswire.com
OneStream, Inc. $OS Shares Sold by Quantbot Technologies LP
Mar 09, 2026 01:02 AM · defenseworld.net
ONESTREAM ANALYSIS: Is $24.00 Per Share a Fair Stockholder Buyout Offer? Kaskela Law Firm Announces Investigation into Fairness of Buyout Offer and Encourages Investors to Contact the Firm - OS
Mar 01, 2026 02:24 PM · newsfilecorp.com
Kaskela Law Firm Announces Investigation into Fairness of Impending OneStream, Inc. (NASDAQ: OS) Shareholder Buyout and Encourages Current OS Shareholders to Contact the Firm
Feb 28, 2026 02:00 AM · globenewswire.com
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Feb 27, 2026 05:15 AM · businesswire.com
Onestream (OS) Reports Q4 Earnings: What Key Metrics Have to Say
Feb 26, 2026 02:01 PM · zacks.com